Table 1.
Sociodemographic features of the patients, characteristics of the disease and quality-of-life indicators.
| Variables Patients (n = 31) | |||||
|---|---|---|---|---|---|
| Sociodemographic features | |||||
| Age (years) | 46.41 (SD 8.92) | Occupation | Employed | 74.2% (23/31) | |
| Unemployed | 25.8% (8/31) | ||||
| Sex (%) | Male: | 35.5% (11/31) | Educational level | No studies or compulsory education | 19.4% (6/31) |
| Female: | 64.5% (20/31) | Professional or university studies | 80.6% (25/31) | ||
| Disease characteristics | |||||
| Disease duration (years) | 10.70 (SD 11.67) | Urticaria Control Test score | 16.29 (SD 6.73) | ||
| Disease duration | <10 years | 61.3% (19/31) | Current treatment for CSU | Antihistamines | 61.3% (19/31) |
| >10 years | 38.7% (12/31) | Omalizumab | 38.7% (12/31) | ||
| Quality-of-life indicators | |||||
| DLQI | 10.35 (SD 7.24) | Overall CUQOL | 33.45 (SD 21.61) | ||
| DS14 (% of positive test) | 29% (9/31) | PSQI | 10.16 (SD 4.53) | ||
| HADS depression (% of positive test) | 48.4% (15/31) | HADS Anxiety (% of positive test) | 38.7% (12/31) | ||
| FSFI (% of female sexual dysfunction) | 60% (12/20) | IIEF (% of male sexual dysfunction) | 54.5% (6/11) | ||
CUQOL: Chronic Urticaria Quality of Life questionnaire; DLQI: Dermatology Quality of Life Index; DS14: Questionnaire for Type D personality; FSFI: Female Sexual Funcion Index; HADS: Hospital Anxiety and Depression Scale; IIEF: International Index of Erectile Funcion; PSQI: Pittsburg Sleep Quality Index; SD: Standard desviation.